Archived explainer. For the current picture see today's RDY page.
DR REDDYS LABS LTD ADR (RDY) is down -5.25% in the latest session. Our newswire has captured 4 stories on RDY across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Dr. Reddy's Laboratories (RDY) stock fell 5.25% to $11.90 in early trading on July 22, 2026, as mixed results from its first-quarter earnings report weighed on investor sentiment. The company reported GAAP earnings per share of $0.06 and revenue of $853 million, which beat estimates by $7.59 million but marked a 5.5% year-over-year decline. The stock opened with a -1.3% gap down and continued to decline through the session, reaching a low of $11.85 before settling near $11.90.
Dr. Reddy's released its Q1 FY27 results, disclosing the earnings and revenue figures alongside a Form 6-K filing with the U.S. Securities and Exchange Commission. The company also announced the appointment of Dr. Sridevi Kh, a biopharmaceutical veteran, to strengthen its biologics leadership. Despite these strategic moves, the revenue decline and earnings shortfall relative to expectations contributed to the stock's downward momentum. The company also highlighted challenges in moving generic semaglutide to the U.S. market due to the tariff environment and ongoing efforts to resume supplies.
RDY opened at $12.40 and quickly declined, reaching a session low of $11.85. The stock traded at $11.89 in the last 5-minute bar, with volume of 0.2 million shares, below its 3-month average. The stock is currently trading within its 52-week range of $12.19 to $15.67. With a market cap of $10.5 billion and a P/E ratio of 23.1, the stock has shown a 3.2% revenue growth over the trailing twelve months and maintains a net margin of 12.8%. The stock’s beta of 0.26 indicates low volatility relative to the market.
Dr. Reddy's will host its Q1 earnings conference call on July 22, where management is expected to provide further details on its semaglutide strategy and operational progress. Investors will also monitor the broader coverage landscape for analyst reactions and potential follow-up actions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Dr. Reddy's press release (RDY): Q1 GAAP EPS of $0.06. Revenue of $853M (-5.5% Y/Y) beats by $7.59M. Operating Working Capital: As on 30th June 2026 at ₹143.5 billion. Capital Expenditu
Dr Reddy’s Laboratories ( ($RDY) ) has issued an announcement. Dr. Reddy’s Laboratories has filed a Form 6-K with the U.S. Securities and Exchange Commission dated ...
Dr Reddy’s Laboratories ( ($RDY) ) just unveiled an update. On July 22, 2026, Dr. Reddy’s Board approved the appointment of biopharmaceutical veteran Dr. Sridevi Kh...
Dr. Reddy's (RDY) reports Q1 earnings July 22 before market open.
More on RDY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RDY move explainers: 2026-07-23 · 2026-07-22